PMID: 11920635Mar 29, 2002Paper

Role of low nuclear grading of renal carcinoma cells in the functional profile of tumor-infiltrating T cells

International Journal of Cancer. Journal International Du Cancer
Luca PuccettiEnrico Maggi

Abstract

Tumor-infiltrating lymphocytes (TILs) from biopsies of 9 selected patients with pT1pN0M0 renal cell carcinoma (RCC) were analyzed at the clonal level for phenotypic distribution, cytokine secretion profile and antitumor cell proliferation and cytotoxicity. T-cell clones generated from RCCs were able to produce higher amounts of interleukin-4 (IL-4) and interferon-gamma (IFN-gamma) than the corresponding clones derived from peripheral blood mononuclear cells, thus suggesting a recruitment into tumors of T cells with peculiar functions. Moreover, CD4+ T-cell clones generated from TILs of nuclear grading 2 (G2)-type RCC patients produced significantly higher amounts of IL-4 and IL-10 and lower amounts of IFN-gamma than the corresponding clones generated from G1-type RCC and 2 renal angiomyolipoma (AML) patients. In addition, T-cell clones generated from lymphocytes infiltrating the peritumoral areas of G2-type, but not those from G1-type, RCC patients produced higher and lower amounts of IL-4 and IFN-gamma, respectively, than the corresponding clones derived from intratumoral T cells of the same patients. The proportion of T-cell clones derived from G2-type tumors and proliferating to autologous tumor cells (ATCs) was significantl...Continue Reading

References

Aug 1, 1992·Urology·D T Uehling, W H Richards
Jan 1, 1989·Advances in Immunology·T R Mosmann, R L Coffman
Oct 1, 1982·The American Journal of Surgical Pathology·S A FuhrmanC Limas
Aug 1, 1995·Current Opinion in Immunology·L Romani, D H Howard
Nov 3, 1995·International Journal of Cancer. Journal International Du Cancer·H NakagomiR Kiessling
Oct 4, 1995·Journal of the National Cancer Institute·P GhoshA C Ochoa
Jun 9, 1995·International Journal of Cancer. Journal International Du Cancer·Q WangR M Bukowski
Jan 1, 1994·Annual Review of Immunology·S Romagnani
Oct 1, 1993·The Journal of Experimental Medicine·M J BrundaM K Gately
Mar 1, 1993·The Journal of Clinical Investigation·M YamamuraR L Moy
May 1, 1993·Current Opinion in Oncology·P D Savage
Jul 1, 1995·International Immunology·M C Ruzek, A Mathur
Jan 1, 1997·Cancer Immunology, Immunotherapy : CII·T TakeuchiK Kawabe
Jun 1, 1997·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M EngelhardtU Brennscheidt
Jul 25, 1998·International Immunology·G Terres, R L Coffman
Sep 2, 1998·Immunology and Cell Biology·C OliveM C Falk
Apr 28, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R J MotzerE M Metz
Sep 7, 2000·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·C A AkdisK Blaser
Oct 12, 2000·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·L J Burke, A Baniahmad

❮ Previous
Next ❯

Citations

Jun 10, 2004·Pathology Oncology Research : POR·Thanaa el-A HelalRemon M Fahmy
Jun 30, 2004·Radiation Research·William H McBrideYu-Pei Liao

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Related Papers

Cancer Immunology, Immunotherapy : CII
G J Dougherty, William H McBride
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
J W DenhamW Dörr
© 2022 Meta ULC. All rights reserved